1. Home
  2. IPHA vs EDF Comparison

IPHA vs EDF Comparison

Compare IPHA & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.96

Market Cap

174.2M

Sector

Health Care

ML Signal

HOLD

Logo Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

EDF

Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

HOLD

Current Price

$4.88

Market Cap

154.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPHA
EDF
Founded
1999
2010
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
174.2M
154.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
IPHA
EDF
Price
$1.96
$4.88
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
565.0K
160.6K
Earning Date
09-17-2025
01-01-0001
Dividend Yield
N/A
13.14%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,839,695.00
N/A
Revenue This Year
$22.29
N/A
Revenue Next Year
$43.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.43
$3.51
52 Week High
$3.51
$5.50

Technical Indicators

Market Signals
Indicator
IPHA
EDF
Relative Strength Index (RSI) 50.64 43.99
Support Level $1.85 $4.88
Resistance Level $2.01 $4.95
Average True Range (ATR) 0.08 0.05
MACD 0.01 0.00
Stochastic Oscillator 69.64 53.33

Price Performance

Historical Comparison
IPHA
EDF

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.

Share on Social Networks: